EBITDA: Income before interest, taxes, depreciation and amortization.
MIRA Pharmaceuticals, Inc. (MIRA) had EBITDA of $-10.49M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-32.00M |
|
-- |
|
-- |
|
$10.49M |
|
$-10.49M |
|
$0.05M |
|
$-10.44M |
|
$-10.41M |
|
$-10.44M |
|
$-10.44M |
|
$-10.44M |
|
$-10.41M |
|
$-10.49M |
|
|
EBITDA |
$-10.49M |
23.69M |
|
23.69M |
|
$-1.35 |
|
$-1.35 |
|
| Balance Sheet Financials | |
$11.06M |
|
-- |
|
$0.04M |
|
$11.09M |
|
$0.70M |
|
-- |
|
-- |
|
$0.70M |
|
$10.39M |
|
$10.39M |
|
$10.39M |
|
41.94M |
|
| Cash Flow Statement Financials | |
$-4.66M |
|
-- |
|
$8.18M |
|
$2.83M |
|
$6.35M |
|
$3.51M |
|
$6.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.66M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-100.49% |
|
-100.49% |
|
-94.13% |
|
-100.49% |
|
$0.25 |
|
$-0.20 |
|
$-0.20 |
|